The Elecsys® Anti-SARS-CoV-2 and Elecsys® Anti-SARS-CoV-2 S antibody assays: Differentiating between vaccination and infection, and assessing long-term performance
Authors:
Open Access
- 18 July 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (7) , e0305613
Abstract
Introduction: Serological surveillance is useful for assessing SARS-CoV-2 immunity in populations. To effectively study the presence and persistence of antibodies, it is necessary to distinguish between persons with past infection, and persons who only received vaccination. Knowledge of the duration of antibody persistence is essential for correct interpretation of surveillance results. Methods: Starting in April 2020, waning of SARS-CoV-2 antibodies was studied in a longitudinal cohort study of 495 SARS-CoV-2 antibody-positive Dutch blood donors, not pre-selected by PCR testing or disease severity. Additionally, in May 2021, a sample of donors representative for the Dutch population was tested for antibodies against the SARS-CoV-2 spike (S) protein, using the Wantai Ab ELISA and the Elecsys® Anti-SARS-CoV-2 S assay; and for antibodies against the nucleocapsid protein, which indicate past infection, using the Elecsys® Anti-SARS-CoV-2 assay. Results: The anti-S response in donors that were infected in April or May 2020 remained positive in 100% of donors in the Elecsys® Anti-SARS-CoV-2 S assay one year after infection, after which follow up of waning was no longer possible because of large scale vaccination. The anti-nucleocapsid response results were still positive in approximately 80% of donors two years after infection. In May 2021, 51% of the donors showed anti-S reactivity and 16.8% tested positive for anti-nucleocapsid antibodies. Conclusion: Infection with SARS-CoV-2 resulted in spike and nucleocapsid antibody levels still detectable in the majority of donors 1–2 years after infection. In May 2021, 51% of donors were vaccinated and 16.8% had had an infection. Thus, both Elecsys® SARS-CoV-2 antibody assays can be used to reliably assess the vaccination and infection status of individuals.Keywords
Funding Information
- Stichting Sanquin Bloedvoorziening (PPOC21-05)
- Stichting Sanquin Bloedvoorziening (PPOC20-01)
- Ministerie van Volksgezondheid, Welzijn en Sport
This publication has 12 references indexed in Scilit:
- Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related ApplicationsEmerging Infectious Diseases, 2022
- Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassayJournal of Virological Methods, 2021
- Low awareness of past SARS-CoV-2 infection in healthy plasma donorsCell Reports Medicine, 2021
- Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemicScience, 2021
- Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the NetherlandsNature Communications, 2020
- Coronavirus biology and replication: implications for SARS-CoV-2Nature Reviews Microbiology, 2020
- Analytical and Clinical Evaluation of the Automated Elecsys Anti–SARS-CoV-2 Antibody Assay on the Roche cobas e602 AnalyzerAmerican Journal of Clinical Pathology, 2020
- Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease PatientsEmerging Infectious Diseases, 2020
- Interpreting Diagnostic Tests for SARS-CoV-2JAMA, 2020
- The healthy donor effect: a matter of selection bias and confoundingTransfusion, 2011